BioAgilytix names Euan Menzies CEO, adds former Labcorp CEO David King to board after $2.5B deal


A Durham company with hundreds of employees has a new CEO in the wake of a buyout that values the firm at $2.5 billion.

Previous Blood cancer specialist blends curiosity and persistence in studying chronic lymphocytic leukemia
Next 5 things to know today: Relocated brunch spot opens in Placerville